Published in Int J Oncol on September 01, 2001
DNA methylation in hepatocellular carcinoma. World J Gastroenterol (2008) 1.77
CpG methylation of MGMT and hMLH1 promoter in hepatocellular carcinoma associated with hepatitis viral infection. Br J Cancer (2003) 0.98
Epigenomics and ovarian carcinoma. Biomark Med (2010) 0.91
Involvement of DNA damage response pathways in hepatocellular carcinoma. Biomed Res Int (2014) 0.84
Mismatch repair genes (hMLH1, hPMS1, hPMS2, GTBP/hMSH6, hMSH2) in the pathogenesis of hepatocellular carcinoma. World J Gastroenterol (2005) 0.83
Promoter methylation of MLH1, PMS2, MSH2 and p16 is a phenomenon of advanced-stage HCCs. PLoS One (2014) 0.79
Aberrant crypt foci: the case for inclusion as a biomarker for colon cancer. Cancers (Basel) (2010) 0.76
Expression of DNA-repair proteins and their significance in pancreatic cancer and non-cancerous pancreatic tissues of Sprague-Dawley rats. World J Surg Oncol (2014) 0.75
Mutations in the ST7/RAY1/HELG locus rarely occur in primary colorectal, gastric, and hepatocellular carcinomas. Br J Cancer (2003) 0.75
Low Levels of Microsatellite Instability at Simple Repeated Sequences Commonly Occur in Human Hepatocellular Carcinoma. Cancer Genomics Proteomics (2017) 0.75
The liver: another organ involved in Muir Torre syndrome? Fam Cancer (2012) 0.75
Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med (1996) 10.60
APC mutations occur early during colorectal tumorigenesis. Nature (1992) 9.50
Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med (2000) 5.68
Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res (1998) 4.39
Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. JAMA (1995) 3.84
Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers. J Natl Cancer Inst (1999) 3.46
Microsatellite instability in colorectal cancer: different mutator phenotypes and the principal involvement of hMLH1. Cancer Res (1998) 3.36
Mutations in AXIN2 cause colorectal cancer with defective mismatch repair by activating beta-catenin/TCF signalling. Nat Genet (2000) 3.33
Actin mutations in dilated cardiomyopathy, a heritable form of heart failure. Science (1998) 3.22
Length of uninterrupted CGG repeats determines instability in the FMR1 gene. Nat Genet (1994) 3.22
Altered expression of hMSH2 and hMLH1 in tumors with microsatellite instability and genetic alterations in mismatch repair genes. Cancer Res (1996) 2.89
17q23 amplifications in breast cancer involve the PAT1, RAD51C, PS6K, and SIGma1B genes. Cancer Res (2000) 2.81
BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. J Med Genet (2004) 2.75
The frequency of hereditary defective mismatch repair in a prospective series of unselected colorectal carcinomas. Am J Hum Genet (2001) 2.68
Hepatocyte apoptosis after bile duct ligation in the mouse involves Fas. Gastroenterology (1999) 2.56
Brunner's gland hamartomas: clinical presentation and pathological features of 27 cases. Am J Gastroenterol (1995) 2.52
Hippocampal volumes in cognitively normal persons at genetic risk for Alzheimer's disease. Ann Neurol (1998) 2.48
Increased HER2 with U.S. Food and Drug Administration-approved antibody. J Clin Oncol (1999) 2.48
Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas. Oncogene (2012) 2.41
Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res (2000) 2.38
Diagnosis and monitoring of Whipple disease by polymerase chain reaction. Ann Intern Med (1997) 2.38
Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. Gastroenterology (2001) 2.30
Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology (2000) 2.25
Pan-colonic decrease in interstitial cells of Cajal in patients with slow transit constipation. Gut (2002) 2.24
Treatment of eosinophilic esophagitis with inhaled corticosteroids. J Pediatr Gastroenterol Nutr (1998) 2.05
Secular trends in the epidemiology and outcome of Barrett's oesophagus in Olmsted County, Minnesota. Gut (2001) 2.05
Denaturing high performance liquid chromatography (DHPLC) used in the detection of germline and somatic mutations. Nucleic Acids Res (1998) 1.99
Increased risk for cancer in patients with the Peutz-Jeghers syndrome. Ann Intern Med (1998) 1.96
Testicular lymphoma is associated with a high incidence of extranodal recurrence. Cancer (2000) 1.95
Hepatocyte apoptosis is a pathologic feature of human alcoholic hepatitis. J Hepatol (2001) 1.93
Sequence analysis of the fragile X trinucleotide repeat: implications for the origin of the fragile X mutation. Hum Mol Genet (1994) 1.90
Hippocampal atrophy and apolipoprotein E genotype are independently associated with Alzheimer's disease. Ann Neurol (1998) 1.86
Apolipoprotein E: risk factor for Alzheimer disease. Am J Hum Genet (1994) 1.83
Spontaneous diabetes mellitus in transgenic mice expressing human islet amyloid polypeptide. Proc Natl Acad Sci U S A (1996) 1.81
Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol (2001) 1.76
Microsatellite instability and mutation analysis of hMSH2 and hMLH1 in patients with sporadic, familial and hereditary colorectal cancer. Hum Mol Genet (1996) 1.76
PTEN induces chemosensitivity in PTEN-mutated prostate cancer cells by suppression of Bcl-2 expression. J Biol Chem (2001) 1.72
Analysis of a CGG sequence at the FMR-1 locus in fragile X families and in the general population. Am J Hum Genet (1993) 1.71
Evidence for a prostate cancer-susceptibility locus on chromosome 20. Am J Hum Genet (2000) 1.69
High functioning fragile X males: demonstration of an unmethylated fully expanded FMR-1 mutation associated with protein expression. Am J Med Genet (1994) 1.68
p53 expression in neurofibroma and malignant peripheral nerve sheath tumor. An immunohistochemical study of sporadic and NF1-associated tumors. Am J Clin Pathol (1996) 1.67
Transcriptional complementarity in breast cancer: application to detection of circulating tumor cells. Mol Diagn (2001) 1.67
E-cadherin germline mutations define an inherited cancer syndrome dominated by diffuse gastric cancer. Hum Mutat (1999) 1.65
Cystic fibrosis and the phenotypic expression of autosomal dominant polycystic kidney disease. Am J Kidney Dis (1998) 1.64
Integrations of the hepatitis B virus (HBV) and human papillomavirus (HPV) into the human telomerase reverse transcriptase (hTERT) gene in liver and cervical cancers. Oncogene (2003) 1.63
Evidence for autosomal dominant inheritance of prostate cancer. Am J Hum Genet (1998) 1.63
Differentiation of primary and metastatic clear cell tumors in the liver by in situ hybridization for albumin messenger RNA. Am J Surg Pathol (2000) 1.60
Immunohistochemical localization of the 1,25(OH)2D3 receptor and calbindin D28k in human and rat pancreas. Am J Physiol (1994) 1.50
The location of the Philadelphia chromosomal breakpoint site and prognosis in chronic granulocytic leukemia. Leukemia (1990) 1.49
Iron overload in cirrhosis-HFE genotypes and outcome after liver transplantation. Hepatology (2000) 1.45
Genotype prediction in the fragile X syndrome. J Med Genet (1991) 1.45
Molecular and cytokinetic pretreatment risk assessment in endometrial carcinoma. Gynecol Oncol (2000) 1.43
Rapid, nonradioactive screening for mutations in exons 10, 11, and 16 of the RET protooncogene associated with inherited medullary thyroid carcinoma. Clin Chem (1997) 1.42
p53 mutations and microsatellite instability in sporadic gastric cancer: when guardians fail. Cancer Res (1994) 1.42
Genetic mapping of new DNA probes at Xq27 defines a strategy for DNA studies in the fragile X syndrome. Am J Hum Genet (1991) 1.38
Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis. Br J Cancer (2009) 1.38
Candidate-gene association studies with pedigree data: controlling for environmental covariates. Genet Epidemiol (2003) 1.36
Epigenetic silencing of HSulf-1 in ovarian cancer:implications in chemoresistance. Oncogene (2007) 1.36
Abnormalities of sodium and H2O handling in chronic obstructive lung disease. Arch Intern Med (1982) 1.35
Germline E-cadherin gene mutations: is prophylactic total gastrectomy indicated? Cancer (2001) 1.35
Alpha1-antitrypsin deficiency allele carriers among lung cancer patients. Cancer Epidemiol Biomarkers Prev (1999) 1.32
The characterization of the common fragile site FRA16D and its involvement in multiple myeloma translocations. Genomics (2000) 1.31
The genomic organization of human dystrobrevin. Neurogenetics (1997) 1.29
The premortem recognition of systemic senile amyloidosis with cardiac involvement. Am J Med (1996) 1.28
Higher risk of mismatch repair-deficient colorectal cancer in alpha(1)-antitrypsin deficiency carriers and cigarette smokers. Mol Genet Metab (2000) 1.28
Allelic imbalance and microsatellite instability in prostatic adenocarcinoma. Cancer Res (1996) 1.28
Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res (2000) 1.28
Molecular markers in male breast carcinoma. Cancer (1998) 1.26
BRCA1 and BRCA2 have a limited role in familial prostate cancer. Cancer Res (2000) 1.25
Role of HPC2/ELAC2 in hereditary prostate cancer. Cancer Res (2001) 1.24
Genetic and physical mapping of a novel region close to the fragile X site on the human X chromosome. Genomics (1989) 1.24
The genetic basis of colorectal cancer in a population-based incident cohort with a high rate of familial disease. Gut (2010) 1.23
The gene for HMSN2C maps to 12q23-24: a region of neuromuscular disorders. Neurology (2003) 1.22
Genetic heterogeneity in Peutz-Jeghers syndrome. Hum Mutat (2000) 1.22
Isolated supravalvular aortic stenosis: functional haploinsufficiency of the elastin gene as a result of nonsense-mediated decay. Hum Genet (2000) 1.20
Preclinical memory decline in cognitively normal apolipoprotein E-epsilon4 homozygotes. Neurology (1999) 1.20
HMSH6 alterations in patients with microsatellite instability-low colorectal cancer. Cancer Res (2000) 1.20
Microsatellite instability in Muir-Torre syndrome. Cancer Res (1994) 1.19
Hepatocytes in the bile duct-ligated rat express Bcl-2. Am J Physiol (1997) 1.19
Immunohistochemical localization of transforming growth factor-beta 1 in the nonnecrotizing granulomas of pulmonary sarcoidosis. Am J Respir Crit Care Med (1994) 1.18
Synthesis of renin by tubulocystic epithelium in autosomal-dominant polycystic kidney disease. Kidney Int (1992) 1.18
An efficient method for the extraction of DNA from formalin-fixed, paraffin-embedded tissue by sonication. Biotechniques (1991) 1.18
Representative cDNA libraries and their utility in gene expression profiling. Biotechniques (1999) 1.17
Paget's disease of the perianal region--an aggressive disease? Dis Colon Rectum (1997) 1.13
The reliability of immunohistochemistry as a prescreening method for the diagnosis of hereditary nonpolyposis colorectal cancer (HNPCC)--results of an international collaborative study. Fam Cancer (2001) 1.13